BMS at ACR Convergence 2020
Intended for U.S. scientific audiences only.
he American College of Rheumatology (ACR) Convergence 2020 is an important opportunity to review and share the latest breakthroughs and research for patients living with rheumatic diseases. At this year’s meeting, we are presenting data on three assets spanning four disease areas, including rheumatoid arthritis, juvenile idiopathic arthritis, lupus and psoriatic arthritis.
In the face of unprecedented challenges over the past year, we’ve remained steadfast in our dedication to the rheumatology community and look forward to showcasing research that has the potential to positively impact people living with immune-mediated diseases.
Hear from Samit Hirawat, M.D., executive vice president, chief medical officer, Global Drug Development, about Bristol Myers Squibb’s presence at the American College of Rheumatology (ACR) Convergence, underscoring our enduring commitment to patients living with immune-mediated diseases.
Our diverse, promising pipeline and research on currently available therapies are driven by our focus on offering innovative medicines that transform patients’ lives. Read about how our scientists are addressing some of the most challenging diseases of our time and advancing research across numerous immune-mediated diseases.
Shalabh Singhal, executive director, development program lead, Rheumatology, explains how by targeting the tyrosine kinase 2 (TYK2) pathway, researchers can further our understanding of how to improve care for psoriatic disease.
Our research in Immunology and Rheumatology spans a number of diseases and pathways of focus. Learn more below.